Company updates
Myosin Therapeutics Announces Key Additions to Its Team as It Prepares to Start Multiple Clinical Trials in Q1 2025
Jupiter, FL – [October 2nd, 2024] – Myosin Therapeutics is pleased to announce the addition...
Financial updates and company news at Myosin Therapeutics
Company updates
Myosin Therapeutics’ Patent Portfolio Strengthened with New Issued Statuses in Australia, Japan, Canada, and Korea
Jupiter, FL – [September 12th, 2024] – Myosin Therapeutics is pleased to announce the expansion...
Company updates
Myosin Therapeutics Announces Successful Completion of GMP Drug Substance Manufacturing Campaign for MT-125
Jupiter, FL – [August 31st, 2024] – Myosin Therapeutics is pleased to announce that it...
Company updates
Today, Myosin Therapeutics Announces FDA Orphan Drug Designation for MT-125 for the Treatment of Malignant Gliomas
Jupiter, FL – [February 21, 2024] – Today, Myosin Therapeutics is pleased to announce that...
Company updates
Myosin Therapeutics Transitions MT-110 to GMP Manufacturing After Meeting Milestones in NIH Blueprint Neurotherapeutics Program
Jupiter, FL – [August 1st, 2023] – Myosin Therapeutics is pleased to announce the successful...
Company updates
Dr. Courtney Miller Honored with BioFlorida’s 2022 Weaver H. Gaines Entrepreneur of the Year Award
Jupiter, FL – [November 15, 2022] – Myosin Therapeutics is honored to announce that its...
